ANXA2
ATC code L01
Abemaciclib
Acalabrutinib
Accelerated Approval
Adagrasib
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
Amivantamab
Anaplastic lymphoma kinase
Antineoplastic
Asciminib
Atezolizumab
Atezolizumab/hyaluronidase
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Baricitinib
Bcr-abl fusion protein
Belantamab mafodotin
Bermekimab
Bevacizumab
Binimetinib
Blinatumomab
Bone marrow suppression
Bosutinib
Breakthrough therapy
Breast cancer
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
C-Met
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK2
CDK4
CDK6
Cabozantinib
Cancer
Cancer immunotherapy
Capmatinib
Catumaxomab
Cediranib
Cell (biology)
Cell cycle
Cell cycle checkpoint
Cemiplimab
Ceritinib
Cetuximab
Cobimetinib
Copanlisib
Cosibelimab
Crizotinib
Cyclin-dependent kinase
Cyclin-dependent kinase inhibitor protein
Dabrafenib
Dacomitinib
Dalpiciclib
Daratumumab
Dasatinib
Denileukin diftitox
Dinaciclib
Dinutuximab beta
Doi (identifier)
Dostarlimab
Durvalumab
Duvelisib
EML4
Edrecolomab
Elotuzumab
Elranatamab
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
Estrogen receptor
Everolimus
Exotoxin
Fedratinib
Fibroblast growth factor receptor
Filgotinib
Food and Drug Administration
Fruquintinib
Fulvestrant
Fusion protein
Futibatinib
G1 Therapeutics
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
HER2
HER2/neu
HER2 negative
HER2 negative breast cancer
Hdl (identifier)
Hedgehog signaling pathway
Hormone receptor
Hormone receptor positive breast tumor
ISSN (identifier)
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Inavolisib
Infigratinib
Inotuzumab ozogamicin
Interleukin 2
Ipilimumab
Isatuximab
Janus kinase
KRAS
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Letrozole
Leukemia
Loncastuximab tesirine
Lorlatinib
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Masitinib
Melanoma
Metastatic breast cancer
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Moxetumomab pasudotox
Myeloid
Naxitamab
Necitumumab
Neratinib
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Oportuzumab monatox
Orelabrutinib
Orphan drug
Osimertinib
P1446A-05
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pazopanib
Pembrolizumab
Pemigatinib
Pertuzumab
Pexidartinib
Pi3K inhibitor
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Ponatinib
Pralsetinib
Priority review
Proapoptotic
Prohibitin
Prolgolimab
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Receptor tyrosine kinase
Regorafenib
Repotrectinib
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Ripretinib
Rituximab
Rociletinib
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Seliciclib
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Sirolimus
Small-cell carcinoma
Solid tumors
Sonidegib
Sorafenib
Sotorasib
Src (gene)
Sugemalimab
Sunitinib
Tafasitamab
Talquetamab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Teclistamab
Temsirolimus
Tepotinib
Tislelizumab
Tisotumab vedotin
Tissue (biology)
Tivozanib
Toceranib
Toripalimab
Tositumomab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tyrosine kinase inhibitor
US FDA
VEGF receptors
Vandetanib
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vemurafenib
Venetoclax
Vismodegib
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab
Zotiraciclib